Saturday, 31 October 2026European Markets

DEKUPLE And SCHIBSTED SER. B Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(vianews) - dekuple (dkupl.pa) is among this list of stock assets with the highest dividend rate and return on equity on the communication services sector.

financial asset price forward dividend yield return on equity
dekuple (dkupl.pa) €30.20 2.81% 29.13%
schibsted ser. b (schb.ol) kr331.40 0.62% 43.07%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. dekuple (dkupl.pa)

2.81% forward dividend yield and 29.13% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company designs, markets, and implements customer loyalty and relationship management services; markets and sells magazine press subscriptions; and offers marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering agency, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €2.25.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 13.42. meaning, the purchaser of the share is investing €13.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.13%.

revenue growth

year-on-year quarterly revenue growth grew by 12.3%, now sitting on 199.66m for the twelve trailing months.

yearly top and bottom value

dekuple's stock is valued at €30.20 at 02:30 est, way below its 52-week high of €39.90 and way higher than its 52-week low of €21.70.

more news about dekuple.

2. schibsted ser. b (schb.ol)

0.62% forward dividend yield and 43.07% return on equity

schibsted asa, together with its subsidiaries, operates as a media company. the company operates through nordic marketplaces, news media, delivery and growth & investments segments. it operates online classifieds that provide technology-based services to connect buyers and sellers, and facilitate transactions, including job offers, real estate, cars, travel, consumer goods, and others. the company also publishes newspapers under the vg, aftenposten, e24, bergens tidende, stavanger aftenblad, aftonbladet, svenska dagbladet, and omni brands in paper and digital format; and operates podme, a podcast platform. in addition, the company distributes newspapers and parcels for businesses and consumers under the helthjem and morgenlevering brands. the company operates in norway, sweden, finland, denmark, other european countries, and internationally. schibsted asa was founded in 1839 and is headquartered in oslo, norway.

earnings per share

as for profitability, schibsted ser. b has a trailing twelve months eps of kr72.

pe ratio

schibsted ser. b has a trailing twelve months price to earnings ratio of 4.6. meaning, the purchaser of the share is investing kr4.6 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 43.07%.

more news about schibsted ser. b.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com